Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as tirzepatide (Mounjaro), are widely used for type 2 diabetes and obesity, but their effects on drug metabolism and immune regulation remain areas of concern. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.